NEOPROFEN (Ibuprofen Lysine) Patent Expiration, LOE Window & CMS Spending

NEOPROFEN (Ibuprofen Lysine) by Recordati Rare Diseases: FDA Orange Book core substance LOE 2032-03-02, 0 AB generics, $0 2024 CMS Part D & Medicaid spend, and 1 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorRecordati Rare Diseases
FDA Application & PathwayN021903 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2032-03-02
Last Listed Patent or Exclusivity Date2032-03-02
Orange Book Patents (*PED Extensions)1 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)1 WAC filings (max 32.5% 2-yr change)